Get the Stockscreener App
27.93
0.53%
-0.15
After Hours:
27.92
-0.010
-0.04%
Enliven Therapeutics Inc stock is traded at $27.93, with a volume of 349.03K.
It is down -0.53% in the last 24 hours and up +7.42% over the past month.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. Its product candidates include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
See More
Previous Close:
$28.08
Open:
$28.34
24h Volume:
349.03K
Relative Volume:
0.37
Market Cap:
$1.66B
Revenue:
-
Net Income/Loss:
$-85.21M
P/E Ratio:
-14.78
EPS:
-1.89
Net Cash Flow:
$-68.53M
1W Performance:
+1.20%
1M Performance:
+7.42%
6M Performance:
+57.89%
1Y Performance:
+29.61%
1-Day Range:
$27.85
$28.91
1-Week Range:
$26.77
$30.22
52-Week Range:
$13.30
$30.22
Enliven Therapeutics Inc Stock (ELVN) Company Profile
Name
Enliven Therapeutics Inc
Sector
Industry
Phone
720-647-8519
Address
6200 LOOKOUT ROAD, BOULDER
Compare ELVN vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELVN
Enliven Therapeutics Inc
|
27.93 | 1.67B | 0 | -85.21M | -68.53M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.48 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
754.91 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.16 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.98 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.43 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Enliven Therapeutics Inc Stock (ELVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-16-25 | Initiated | Goldman | Buy |
| Dec-13-24 | Initiated | BTIG Research | Buy |
| Sep-09-24 | Initiated | H.C. Wainwright | Buy |
| Jun-11-24 | Initiated | Robert W. Baird | Outperform |
| Apr-09-24 | Initiated | Mizuho | Buy |
| Mar-29-23 | Initiated | Jefferies | Buy |
View All
Enliven Therapeutics Inc Stock (ELVN) Latest News
Aug Technicals: What drives Enliven Therapeutics Incs stock priceJuly 2025 Recap & Stepwise Trade Signal Implementation - baoquankhu1.vn
Aug Breakouts: Can Enliven Therapeutics Inc disrupt its industryJuly 2025 Macro Moves & Advanced Technical Analysis Signals - baoquankhu1.vn
Enliven Therapeutics (NASDAQ:ELVN) Sets New 1-Year HighWhat's Next? - MarketBeat
Quarterly Trades: Is Enliven Therapeutics Inc a speculative investment2025 Support & Resistance & Free Verified High Yield Trade Plans - baoquankhu1.vn
Aug Highlights: How sensitive is Enliven Therapeutics Inc to inflation2025 Performance Recap & Breakout Confirmation Trade Signals - baoquankhu1.vn
Enliven Therapeutics Chief Scientific Officer Sells ELVN 20K Shares Worth Over $500k - AOL.com
Heron Therapeutics (NASDAQ:HRTX) & Enliven Therapeutics (NASDAQ:ELVN) Head to Head Contrast - Defense World
Update Report: Can Enliven Therapeutics Inc disrupt its industryPortfolio Gains Report & Fast Gaining Stock Reports - baoquankhu1.vn
Assessing Enliven Therapeutics (ELVN) Valuation After CSO Share Sale And Early Leukemia Trial Progress - Sahm
Enliven Therapeutics Executive Sells 20,000 Shares - Intellectia AI
Enliven Therapeutics, Inc. (ELVN) Stock Analysis: A Biotech Pioneer with 61% Potential Upside - DirectorsTalk Interviews
Enliven Therapeutics CFO sells $22,524 in stock - MSN
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Enliven Therapeutics, Inc. (NASDAQ:ELVN) Given Consensus Rating of “Moderate Buy” by Brokerages - Defense World
Aug Sectors: What is DATSs valuation compared to sectorJuly 2025 Big Picture & High Accuracy Investment Signals - baoquankhu1.vn
Market Outlook: Is Enliven Therapeutics Inc attractive for institutional investorsStop Loss & Low Risk High Win Rate Stock Picks - baoquankhu1.vn
Joseph Lyssikatos Sells 20,000 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Enliven Therapeutics director Heyman sells $32,901 in stock By Investing.com - Investing.com South Africa
Day Trade: What hedge funds are buying TSLA2025 Major Catalysts & Technical Buy Zone Confirmations - baoquankhu1.vn
Lyssikatos, Enliven Therapeutics CSO, sells $535k in ELVN stock By Investing.com - Investing.com Canada
Enliven Therapeutics (NASDAQ:ELVN) Director Sells 1,230 Shares - MarketBeat
Enliven Therapeutics director Heyman sells $32,901 in stock - Investing.com
Why (ELVN) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Comparing CytoDyn (OTCMKTS:CYDY) and Enliven Therapeutics (NASDAQ:ELVN) - Defense World
Stocks To Watch: Enliven Therapeutics Sees RS Rating Jump To 85 - Investor's Business Daily
Assessing Enliven Therapeutics (ELVN) Valuation After Positive Phase 1b ENABLE Trial Update - Sahm
Will Enliven Therapeutics Inc. stock see insider buyingChart Signals & Short-Term Swing Trade Alerts - bollywoodhelpline.com
Enliven Therapeutics (NASDAQ:ELVN) Stock Price Up 7.4%Should You Buy? - MarketBeat
Have Enliven Therapeutics Insiders Been Selling Stock? - Sahm
Anish Patel Sells 48,300 Shares of Enliven Therapeutics (NASDAQ:ELVN) Stock - Defense World
Is Enliven Therapeutics Inc. attractive for institutional investorsQuarterly Market Summary & High Return Trade Opportunity Guides - bollywoodhelpline.com
Moving Averages: Does Enliven Therapeutics Inc stock have upside surprise potential2025 Top Decliners & Long-Term Growth Plans - baoquankhu1.vn
Insider Selling: Enliven Therapeutics (NASDAQ:ELVN) COO Sells 48,300 Shares of Stock - MarketBeat
Anish Patel, COO of Enliven Therapeutics, sells $1.35m in ELVN - Investing.com Canada
Enliven Therapeutics: Springing Into 2026 With Data, But I'm Still Cautious (NASDAQ:ELVN) - Seeking Alpha
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares of Stock - Defense World
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 91,198 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Insider Joseph Lyssikatos Sells 41,302 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Richard Heyman Sells 4,285 Shares - MarketBeat
Enliven Therapeutics (NASDAQ:ELVN) Director Sells $241,164.05 in Stock - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares By Investing.com - Investing.com UK
Enliven Therapeutics (NASDAQ:ELVN) Trading Down 8%Here's What Happened - MarketBeat
Enliven Therapeutics CSO Lyssikatos sells $3.47 million in shares - Investing.com India
Enliven Therapeutics Insider Sold Shares Worth $3,476,014, According to a Recent SEC Filing - marketscreener.com
Stocks with rising relative price strength: Enliven Therapeutics - MSN
The $225B Precision Sprint: How Big Pharma is Beating the $170B Patent Cliff - The Spec
Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s Why - Defense World
Assessing Enliven Therapeutics (ELVN) Valuation After Encouraging ENABLE Trial Data - Sahm
Enliven Therapeutics, Inc.Common Stock (NQ: ELVN - FinancialContent
Enliven Therapeutics (NASDAQ:ELVN) Trading 21.1% HigherTime to Buy? - MarketBeat
Enliven Therapeutics stock hits 52-week high at $25.64 By Investing.com - Investing.com India
Enliven Therapeutics Inc Stock (ELVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Enliven Therapeutics Inc Stock (ELVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER |
Jan 20 '26 |
Sale |
26.75 |
20,000 |
535,099 |
745,188 |
| Heyman Richard A. | Director |
Jan 20 '26 |
Sale |
26.75 |
1,230 |
32,902 |
23,877 |
0.36%
1.16%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):